

## References

1. Winter SS, Page-Reeves JM, Page KA, et al. Inclusion of special populations in clinical research: important considerations and guidelines. *J Clin Transl Res*. 2018;4(1):56-69.
2. [?] US Food and Drug Administration. Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs. Final Guidance for Industry. FDA; 2020.
3. [?] Charlton M, Schlichting J, Chioreso C, Ward M, Vikas P. Challenges of rural cancer care in the United States. *Oncology (Williston Park)*. 2015;29(9):633-640.
4. [?] Iezzoni LI. Eliminating health and health care disparities among the growing population of people with disabilities. *Health Aff (Millwood)*. 2011;30(10):1947-1954.
5. [?] DeCormier Plosky W, Ne'eman A, Silverman BC, et al. Excluding people with disabilities from clinical research: eligibility criteria lack clarity and justification. *Health Aff*. 2022;41(10):1423-1432.
6. [?] Miller J, Mello MM, Wallach JD, et al. Evaluation of drug trials in high-, middle-, and low-income countries and local commercial availability of newly approved drugs. *JAMA Netw Open*. 2021;4(5):e217075.
7. [?] US Food and Drug Administration. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. Draft Guidance for Industry. FDA; 2024.
8. [?] US Food and Drug Administration. Patient-Focused Drug Development: Collecting Comprehensive and Representative Input. Final Guidance for Industry. FDA; 2020.
9. [?] US Food and Drug Administration. Patient-Focused Drug Development: Methods to Identify What Is Important to Patients. Final Guidance for Industry. FDA; 2022.
10. [?] US Food and Drug Administration. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. Draft Guidance for Industry. FDA; 2022.
11. [?] US Food and Drug Administration. Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints For Regulatory Decision-Making. Draft Guidance for Industry. FDA; 2023.